Xiaoqi Shao

机构：Guangdong Pharmaceutical University, State Administration of Traditional Chinese Medicine of the People's Republic of China, Key Laboratory of Guangdong Province, Integrated Chinese Medicine (China) · ORCID：0000-0002-8587-6647

发表论文 24 篇 · 总被引 660 次 · h-index 13

代表论文

• Mitochondrial damage and activation of the cytosolic DNA sensor cGAS–STING pathway lead to cardiac pyroptosis and hypertrophy in diabetic cardiomyopathy mice (2022 · Cell Death Discovery · 被引 265)
• Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis (2017 · Molecular Therapy · 被引 62)
• MicroRNA-24-3p alleviates cardiac fibrosis by suppressing cardiac fibroblasts mitophagy via downregulating PHB2 (2022 · Pharmacological Research · 被引 52)
• Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice (2018 · Toxicology and Applied Pharmacology · 被引 40)
• The Chinese medicine Fufang Zhenzhu Tiaozhi capsule protects against atherosclerosis by suppressing EndMT via modulating Akt1/β-catenin signaling pathway (2022 · Journal of Ethnopharmacology · 被引 34)
• The Chinese herbal medicine Fufang Zhenzhu Tiaozhi protects against diabetic cardiomyopathy by alleviating cardiac lipotoxicity-induced oxidative stress and NLRP3-dependent inflammasome activation (2022 · Biomedicine & Pharmacotherapy · 被引 34)